Clinical trial · Interventional
Gemcitabine (GFF) in Patients With Pancreatic Cancer
A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.
NCT00919282CI-TRIAL-00002379GFFcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemcitabine, folinic acid, 5-FU | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gemcitabine/folinic acid/5-FU
- description
- Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
- interventionNames
- Drug: gemcitabine, folinic acid, 5-FU
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- safety of treatment
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histological proved pancreatic cancer * inoperable disease * informed consent * adequate bone marrow reserve Exclusion Criteria: * under 18 years * brain metastasis * lactating woman * life expectancy under 3 months
References
Publications (0)
Data not yet available
No reference posted for this study.